Last reviewed · How we verify
NCT02402400
Sub Lingual Versus Traditional Oral Administration of Ticagrelor in Acute Coronary Syndrome
Phase 4 trial testing Sub Lingual Ticagrelor in Acute Coronary Syndromes in 50 participants. Completed in 1 March 2016.
1 March 2016
Quick facts
| Lead sponsor | Sheba Medical Center |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 July 2015 |
| Primary completion | 1 March 2016 |
| Estimated completion | 1 March 2016 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Sub Lingual Ticagrelor — full drug profile →
Conditions studied
- Acute Coronary Syndromes — all drugs for Acute Coronary Syndromes →
- Non ST Elevation Myocardial Infarction — all drugs for Non ST Elevation Myocardial Infarction →
Sponsor
Sheba Medical Center
Who can join
Adults 18 to 90, any sex, with Acute Coronary Syndromes or Non ST Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Residual platelet reactivity by Platelet Reactivity Units (PRU) VerifyNow 1 hour after ticagrelor LD
Time frame: 1hour
Sponsor's own description
Our goal is to examine sub lingual versus traditional oral administration of ticagrelor in ACS/non ST-elevation Myocardial Infarction (NSTEMI) patients on platelet reactivity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02402400
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Coronary Syndromes
Currently open trials in the same condition.
- NCT07123181 — Oregano and Basil Leaves and Coronary Artery Disease · NA · recruiting
- NCT06927739 — Focused Orticumab Research for Treating Inflammation in Coronary Arteries · Phase 2 · recruiting
- NCT06845826 — Point-of-Care Troponin Testing in the Emergency Department · NA · recruiting
- NCT07268859 — Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea · NA · recruiting
- NCT06954103 — Mechanisms And Prognosis of Stroke-Heart Syndrome · recruiting
Other Sheba Medical Center trials
Trials by the same sponsor.
- NCT07401524 — Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage · Phase 4 · not yet recruiting
- NCT07523373 — Facial Nerve Monitoring During Parotid and Facial Surgery Using a Non-Invasive Patch · NA · not yet recruiting
- NCT07509229 — 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients · Phase 1, PHASE2 · not yet recruiting
- NCT07405723 — Arm Position and Blood Pressure Measurement Accuracy During Pregnancy · NA · recruiting
- NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02402400 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sheba Medical Center
- Last refreshed: 19 March 2016
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02402400.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing